Prognostic Factors and the Role of Adjuvant Chemotherapy in Post-curative Surgery for Dukes B and C Colon Cancers and Survival Outcomes: a Malaysian Experience |
Hassan, Astrid Sinarti
(Clinical Oncology Unit, Faculty of Medicine, National University of Malaysia)
Naicker, Manimalar (Department of Pathology, Faculty of Medicine, National University of Malaysia) Yusof, Khairul Hazdi (Department of Community Health, Faculty of Medicine, National University of Malaysia) Ishak, Wan Zamaniah Wan (Clinical Oncology Unit, Faculty of Medicine, National University of Malaysia) |
1 | Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. DOI |
2 | Andre T, Boni C, Navarro M, et al (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27, 3109-16. DOI |
3 | Ariffin OZ, Nor Saleha (2011). Malaysia Cancer Statistics-Data and Figures. National Cancer Registry Report 2007. |
4 | Benson AB, 3rd, Schrag D, Somerfield MR, et al (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol, 22, 3408-19. DOI |
5 | Bozkurt O, Inanc M, Turkmen E, et al (2014). Clinicopathological characteristics and prognosis of patients according to recurrence time after curative resection for colorectal cancer. Asian Pac J Cancer Prev, 15, 9277-81. DOI |
6 | Buyse M, Piedbois P (2001). Should Dukes' B patients receive adjuvant therapy? A statistical perspective. Semin Oncol, 28, 20-4. DOI |
7 | Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al (2007). Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst, 99, 433-41. DOI |
8 | Chen SL, Bilchik AJ (2006). More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg, 244, 602-10. |
9 | Chiu J, Tang V, Leung R, et al (2014). Efficacy and tolerability of adjuvant oral capecitabine plus intravenous oxaliplatin (XELOX) in Asian patients with colorectal cancer: 4-year analysis. Asian Pac J Cancer Prev, 14, 6585-90. |
10 | Chong VH, Abdullah MS, Telisinghe PU, et al (2009). Colorectal cancer: incidence and trend in Brunei Darussalam. Singapore Med J, 50, 1085-9. |
11 | Compton CC, Fielding LP, Burgart LJ, et al (2000). Prognostic factors in colorectal cancer. College of american pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 979-94. |
12 | Edge SB, Compton CC (2010). The American Joint Committee on Cancer: the 7th edition of theAJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 17, 1471-4. DOI |
13 | Elsamany SA, Alzahrani AS, Mohamed MM, et al (2014). Clinico-pathological patterns and survival outcome of colorectal cancer in young patients: western Saudi Arabia experience. Asian Pac J Cancer Prev, 15, 5239-43. DOI |
14 | Fang XY, Xu WD, Huang Q, et al (2014). 5,10-Methylenetetrahydrofolate reductase polymorphisms and colon cancer risk: a meta-analysis. Asian Pac J Cancer Prev, 15, 8245-50. DOI |
15 | Galizia G, Orditura M, Ferraraccio F, et al (2009). The lymph node ratio is a powerful prognostic factor of node-positive colon cancers undergoing potentially curative surgery. World J Surg, 33, 2704-13. DOI |
16 | Kim MJ, Jeong SY, Choi SJ, et al (2015). Survival Paradox Between Stage IIB/C (T4N0) and Stage IIIA(T1-2N1) Colon Cancer. Ann Surg Oncol, 22, 505-12. DOI |
17 | Kong CK, Roslani AC, Law CW, et al (2010). Impact of socioeconomic class on colorectal cancer patient outcomes in Kuala Lumpur and Kuching, Malaysia. Asian Pac J Cancer Prev, 11, 969-74. |
18 | Magaji BA, Moy FM, Roslani AC, et al (2014). Descriptive epidemiology of colorectal cancer in University Malaya Medical Centre, 2001 to 2010. Asian Pac J Cancer Prev, 15, 6059-64. DOI ScienceOn |
19 | Morris EJ, Maughan NJ, Forman D, et al (2007). Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut, 56, 1419-25. DOI |
20 | McKenzie S, Nelson R, Mailey B, et al (2011). Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer. Cancer, 117, 5493-9. DOI |
21 | Morrison DS, Parr CL, Lam TH, et al (2013). Behavioural and metabolic risk factors for mortality from colon and rectum cancer: analysis of data from the Asia-Pacific Cohort Studies Collaboration. Asian Pac J Cancer Prev, 14, 1083-7. DOI ScienceOn |
22 | Nadoshan JJ, Omranipour R, Beiki O, et al (2013). Prognostic value of lymph node ratios in node positive rectal cancer treated with preoperative chemoradiation. Asian Pac J Cancer Prev, 14, 3769-72. DOI ScienceOn |
23 | O'Connell JB, Maggard MA, Liu JH, et al (2004). Do young colon cancer patients have worse outcomes? World J Surg, 28, 558-62. DOI |
24 | O'Connor ES, Greenblatt DY, LoConte NK, et al (2011). Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol, 29, 3381-8. DOI |
25 | Omranipour R, Mahmoodzadeh H, Safavi F (2014). Prevalence of local recurrence of colorectal cancer at the Iranian Cancer Institute. Asian Pac J Cancer Prev, 15, 8587-9. DOI |
26 | Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol, 4, 68-70. DOI ScienceOn |
27 | Quah HM, Chou JF, Gonen M, et al (2008). Identification of patients with high-risk stage II colon cancer for adjuvant therapy. Dis Colon Rectum, 51, 503-7. DOI |
28 | Schrag D, Rifas-Shiman S, Saltz L, et al (2002). Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol, 20, 3999-4005. DOI |
29 | Quasar Collaborative G, Gray R, Barnwell J, et al (2007). Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet, 370, 2020-9. DOI |
30 | Rosenberg R, Friederichs J, Schuster T, et al (2008). Prognosis of patients with colorectal cancer is associated with lymph node ratio: a single-center analysis of 3,026 patients over a 25-year time period. Ann Surg, 248, 968-78. DOI |
31 | Shah SA, Neoh HM, Rahim SS, et al (2014). Spatial analysis of colorectal cancer cases in Kuala Lumpur. Asian Pac J Cancer Prev, 15, 1149-54. DOI ScienceOn |
32 | Shepherd NA, Baxter KJ, Love SB (1997). The prognostic importance of peritoneal involvement in colonic cancer: a prospective evaluation. Gastroenterology, 112, 1096-102. DOI |
33 | Tsukuma H, Ioka A, Tanaka M (2011). [Incidence and mortality of colorectal cancer--international comparison]. Nihon Rinsho, 69, 45-50. |
34 | Vather R, Sammour T, Kahokehr A, et al (2009). Lymph node evaluation and long-term survival in Stage II and Stage III colon cancer: a national study. Ann Surg Oncol, 16, 585-93. DOI |
35 | Wilkinson NW, Yothers G, Lopa S, et al (2010). Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol, 17, 959-66. DOI |
36 | Wong AC, Stock S, Schrag D, et al (2014). Physicians' beliefs about the benefits and risks of adjuvant therapies for stage ii and stage iii colorectal cancer. J Oncol Pract, 10, 360-7. DOI |
37 | Yun JA, Kim HC, Kim SH, et al (2014). Prognostic significance of perineural invasion in stage IIA colon cancer. ANZ J Surg. |
38 | Yahaya MA, Chin PY, Sulaiman LH, et al (2011). Annual report Ministry of Health, Malaysia. |
39 | Yee YK, Tan VP, Chan P, et al (2009). Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol, 24, 1810-6. DOI |